STEM, INC. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by STEM, INC. on August 28, 2024. The filing addresses a regulatory notice received from the New York Stock Exchange (NYSE) regarding the Company's compliance with continued listing standards.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on listing status and regulatory compliance.
Material Changes and Events
- Listing Deficiency: The Company received notice from the NYSE that its common stock's average closing price fell below $1.00 per share for 30 consecutive trading days, violating Section 802.01C of the NYSE Listed Company Manual.
- Trading Status: Shares continue to trade on the NYSE pending compliance efforts.
- Operational Impact: The notice does not affect business operations, SEC reporting obligations, or trigger defaults under material debt agreements.
Outlook, Management Commentary, and Risks
- Cure Period: The Company has a six-month cure period to regain compliance. It intends to respond to the NYSE within 10 business days of receipt of the notice.
- Compliance Path: To regain compliance, the stock must close at or above $1.00 per share on the last trading day of any calendar month during the cure period, with an average closing price of at least $1.00 over the preceding 30 trading days.
- Risk of Delisting: Failure to meet the cure conditions or maintain other listing requirements could result in delisting.
Key Facts for Investor Verification
- Verify the current stock price and 30-day average to assess proximity to the $1.00 threshold.
- Monitor the Company's formal response to the NYSE within the 10-business-day window.
- Review the press release dated August 30, 2024 (Exhibit 99) for additional management commentary.
- Confirm that no other material debt covenants are tied to stock price performance.